DPP-4 inhibitor 1
Modify Date: 2024-01-13 15:02:27
DPP-4 inhibitor 1 structure
|
Common Name | DPP-4 inhibitor 1 | ||
|---|---|---|---|---|
| CAS Number | 1915007-89-4 | Molecular Weight | 384.35 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H15F3N2O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DPP-4 inhibitor 1DPP-4 inhibitor 1 (compound 5) is a potent and long acting Dipeptidyl peptidase-4 (DPP-4) inhibitor for t treatment of T2DM, with a KD of 0.177 nM[1]. |
| Name | DPP-4 inhibitor 1 |
|---|
| Description | DPP-4 inhibitor 1 (compound 5) is a potent and long acting Dipeptidyl peptidase-4 (DPP-4) inhibitor for t treatment of T2DM, with a KD of 0.177 nM[1]. |
|---|---|
| Related Catalog | |
| Target |
KD: 0.177 nM (DPP-4)[1]. |
| In Vivo | A single-dose oral administration of DPP-4 inhibitor 1 (compound 5) (3 mg/kg) inhibits >80% of DPP-4 activity for more than 7 days in diabetic mice[1]. Administration of DPP-4 inhibitor 1 (compound 5) (3 and 10 mg/kg, p.o., qw for 8 weeks) causes significant reductions in fasting blood glucose (FBG) levels, and the average reduction during the entire treatment period is 24.7 and 33.1%, respectively. Chronic administration of DPP-4 inhibitor 1 (compound 5) (10 mg/kg/week) also significantly improves the glucose tolerance of the diabetic mice[1]. Animal Model: ICR mice[1]. Dosage: 0.3, 3, 10 mg/kg. Administration: Oral, once. Result: Resulted in a time- and dose-dependent inhibition of plasma DPP-4 activity. The active GLP-1 and insulin level were significantly increased compared with the vehicle control. Animal Model: Genetic-type 2 diabetes animal models in db/db Mice[1]. Dosage: 3 and 10 mg/kg. Administration: Oral administration once a week, for 8 weeks. Result: Caused significant reductions in fasting blood glucose (FBG) levels. Improved the glucose tolerance of the diabetic mice significantly. |
| References |
| Molecular Formula | C21H15F3N2O2 |
|---|---|
| Molecular Weight | 384.35 |